Key Takeaways
- Gilead Sciences has entered into an agreement to purchase German biotech firm Tubulis GmbH in a deal valued at up to $5 billion.
- The transaction includes an initial cash payment of $3.15 billion, with additional milestone-based payments potentially reaching $1.85 billion.
- This acquisition strengthens Gilead’s antibody-drug conjugate (ADC) portfolio, with focus areas including ovarian and non-small cell lung cancers.
- RBC Capital Markets increased its GILD price target from $118 to $123 while maintaining a Sector Perform rating.
- Analysts project Yeztugo could surpass Q1 revenue expectations by approximately $180 million, though some concerns exist around long-term compliance rates.
- Multiple Wall Street firms including Cantor Fitzgerald, UBS, and Deutsche Bank maintain bullish stances with price targets reaching $155.
Gilead Sciences (GILD) is making a significant move to bolster its oncology division, announcing plans to acquire Munich-headquartered Tubulis GmbH in an all-cash transaction worth as much as $5 billion.
The pharmaceutical giant will pay $3.15 billion upfront, with an additional $1.85 billion structured as performance-based milestone payments. Financing will come from existing cash reserves and newly issued senior unsecured notes, with the transaction anticipated to close during the second quarter of 2026.
Tubulis specializes in developing antibody-drug conjugates, an innovative class of cancer treatments that deliver chemotherapy agents directly to malignant cells while minimizing damage to surrounding healthy tissue. The company’s flagship candidate, TUB-040, is currently undergoing Phase 1b/2 clinical evaluation for platinum-resistant ovarian cancer and non-small cell lung cancer patients.
CEO Daniel O’Day characterized the enhanced pipeline as potentially representing the most robust and varied collection of assets in Gilead’s corporate history.
Investors responded with modest skepticism, sending shares down approximately 1.37% on Tuesday — a common market reaction when companies commit substantial upfront capital to acquisitions.
RBC Upgrades Target While Maintaining Cautious Outlook
RBC Capital Markets adjusted its GILD price target upward to $123 from the previous $118 mark, though the firm continues to assign a Sector Perform rating — effectively a neutral recommendation. The upgrade stems from encouraging early performance data for Yeztugo, one of Gilead’s recent product launches, based on third-party prescription tracking.
RBC’s analysis suggests Yeztugo revenue for the first quarter could exceed consensus forecasts by roughly $180 million, significantly above the $141 million Street estimate. If accurate, this would represent a substantial positive surprise.
However, the firm injected a note of caution into its assessment. RBC observed that investor expectations for full-year 2026 may already be elevated around the $1 billion mark. Should patient compliance rates or market penetration fall short of projections, these optimistic peak revenue forecasts could require downward revision.
Current compliance tracking sits at approximately 70% according to RBC’s market research — a respectable figure, but one that offers limited cushion for deterioration.
RBC also identified potential headwinds in other business segments. The firm projects HIV-related revenue at $4.8 billion compared to consensus expectations of $4.9 billion, while Veklury revenue is estimated at $141 million versus the Street’s $216 million forecast.
Gilead is scheduled to release first-quarter financial results on April 23.
Wall Street Analysts Maintain Optimistic Views
Several analysts remain decidedly positive on Gilead’s prospects. Cantor Fitzgerald reaffirmed its Overweight recommendation with a $155 price objective, highlighting robust prescription momentum throughout Gilead’s HIV drug portfolio.
UBS similarly sustained its Buy rating, referencing a dramatic 56% sequential increase in Yeztugo sales during February. Deutsche Bank also maintained its Buy recommendation alongside a $155 target, forecasting first-quarter Yeztugo revenue of approximately $118 million.
In a separate development, Gilead has pushed back the expiration date for its tender offer to acquire Arcellx common shares to April 24, 2026. The proposal includes $115.00 per share in cash plus contingent value rights linked to future product sales achievements.
As the April 23 earnings release approaches, market participants will be closely monitoring whether Yeztugo’s impressive early momentum materializes into concrete revenue outperformance.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
